Ten years of anti-vascular endothelial growth factor therapy. - Wikidata - awgldk - TriplyDB

Ten years of anti-vascular endothelial growth factor therapy.

Ten years of anti-vascular endothelial growth factor therapy.

http://www.wikidata.org/entity/Q46407140

about

Cancer Transcriptome Dataset Analysis: Comparing Methods of Pathway and Gene Regulatory Network-Based Cluster Identification.Computational investigation of sphingosine kinase 1 (SphK1) and calcium dependent ERK1/2 activation downstream of VEGFR2 in endothelial cells.Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain.Morphine decreases the pro-angiogenic interaction between breast cancer cells and macrophages in vitro Discovery of pan-VEGF inhibitory peptides directed to the extracellular ligand-binding domains of the VEGF receptors.Galectin-3 Inhibition by a Small-Molecule Inhibitor Reduces Both Pathological Corneal Neovascularization and Fibrosis.Inhibition of VEGFR2 Activation and Its Downstream Signaling to ERK1/2 and Calcium by Thrombospondin-1 (TSP1): In silico Investigation PDGF-CC underlies resistance to VEGF-A inhibition and combinatorial targeting of both suppresses pathological angiogenesis more efficiently.Aptamers as targeted therapeutics: current potential and challenges.Classical VEGF, Notch and Ang signalling in cancer angiogenesis, alternative approaches and future directions (Review).History and conceptual developments in vascular biology and angiogenesis research: a personal view.Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer.Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer.Increased serum levels of vascular endothelial growth factor in pemphigus foliaceus patients with erythroderma.VEGF and Intraocular Neovascularization: From Discovery to Therapy.Modulation of VEGF receptor 2 signaling by protein phosphatases.Determinants of metastatic competency in colorectal cancer.Immunomodulatory Nanomedicine.Therapeutic targeting of the angiopoietin-TIE pathway.VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Tumor angiogenesis revisited: Regulators and clinical implications.The dark side of browning.Epithelial-to-Pericyte Transition in Cancer.Microenvironmental regulation of tumour angiogenesis.Molecular genetics and targeted therapy of WNT-related human diseases (Review).Resistance to metronomic chemotherapy and ways to overcome it.Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.Methylseleninic Acid Provided at Nutritional Selenium Levels Inhibits Angiogenesis by Down-regulating Integrin β3 Signaling Cellular Reparative Mechanisms of Mesenchymal Stem Cells for Retinal Diseases.Normalizing Tumoral Vessels to Treat Cancer: An Out-of-the-Box Strategy Involving TIE2 Pathway.Simple and complex retinal dystrophies are associated with profoundly different disease networks The potential of anti-VEGF (Vasotide) by eye drops to treat proliferative retinopathies.Transcriptome analysis reveals a role for the endothelial ANP-GC-A signaling in interfering with pre-metastatic niche formation by solid cancers.Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy.Recent Advances in SELEX Technology and Aptamer Applications in Biomedicine.Microvascular Density as a Predictive Biomarker for Bevacizumab Survival Benefit in Ovarian Cancer: Back to First Principles?Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy.Therapeutic induction of high endothelial venules (HEVs) to enhance T-cell infiltration in tumors.Lupeol and stigmasterol suppress tumor angiogenesis and inhibit cholangiocarcinoma growth in mice via downregulation of tumor necrosis factor-α.

P2860

Q33569864-270C0B70-D9DB-4B37-809D-C7DA804BB66B Q36273980-168C3639-BB26-4631-A093-0FB361ACBC7E Q36890872-CDC0955E-7AAE-4BFF-8EAB-070F33A46077 Q37168985-E5BD769F-22E1-4DE1-A2F0-9C58016740FF Q37388064-B1F8DD23-6047-4867-9DC9-2C13AD7BABD0 Q37579627-93F23628-A45A-4FEB-9BC9-0A92C08729C8 Q37625434-E83DAF11-BA47-4317-9BDA-DB667010BD50 Q37718460-70D01AA1-02D3-4497-83C3-2D7CD8E00C41 Q38290290-7B1EED50-080B-4344-A1A6-4B0BC5B5B4AC Q38645097-323AAC13-BC71-458C-9A71-738CED6B2422 Q38652259-B9D13E9E-B190-42A0-8637-AAA4AAC51CD0 Q38692304-05A69CBB-F673-49C9-9FE6-E7BB0393C666 Q38707904-C8732041-16B9-4DF4-9DAE-A4B071BD2BEE Q38749030-D3182963-49FA-4CB9-86B9-8C9320708724 Q38924081-C5295134-01A0-4FFF-A802-F61744C84822 Q38978319-17B5D6A8-A63E-4C4E-8C03-5DF7F26F7149 Q39020269-F59029E2-06CA-4425-A00D-B05BDA9FCDE3 Q39085740-C061C1BF-0E80-4648-AE7E-78568CB20694 Q39224331-14C69221-31A6-4BE8-8072-AFF0E07BA5C3 Q39321127-DE601706-8E0E-4ABE-8C08-568D3E35E954 Q39378135-C79ED63C-8316-4DB8-B83F-50C30D1E4858 Q39393740-01ED112F-C0C0-4A13-917D-CE39948C2713 Q39414477-F9E5E648-606D-4997-85B9-85A6D5D01C63 Q39414887-C7704B0D-7DE2-4985-9079-C1808A6092C5 Q39433862-2BE7F0FD-30FB-4180-942A-FC64560ED16A Q39450241-5A689D16-8A37-4ACD-A8F9-593F37B1F830 Q40448516-D673B83B-D016-4574-BBEC-56AFD460DBCC Q41369903-067F59E3-2A39-4336-A856-E7F13AEF9C21 Q41534532-8BFAD240-22B7-4A43-A698-55DD53476EFC Q41572871-8999A39F-8B0C-46B5-B037-EA60AC5B423C Q41710508-F3644F01-77A9-4416-90B1-6A173A5F0DB1 Q41852634-2EC294C8-CDFF-451B-B2CD-AC1F14A09D6F Q42370368-209F988A-AE71-44B8-B96A-F40B3B27C2BC Q42371554-3B8294A1-DA01-413C-AB45-EDA2C85D8F23 Q42644178-BDE026AE-C534-4F63-BCEC-0F7A8EC732BB Q45265302-30F0CCF2-A3B7-475C-A776-E636DA40AB1E Q46016818-358DDB4B-E1DD-45C8-B97F-8CCF86C7F95D Q47099537-8031B195-7013-495A-AC7B-C1B725EA49FD Q47104301-AEB782DA-E108-419E-A235-B94533BA3CBA Q47142939-62858FFD-CC75-41E3-8348-5B4D0DA85410

P2860

Ten years of anti-vascular endothelial growth factor therapy.

http://www.wikidata.org/entity/Q46407140

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Ten years of anti-vascular endothelial growth factor therapy.

@en

Ten years of anti-vascular endothelial growth factor therapy.

@nl

type

label

Ten years of anti-vascular endothelial growth factor therapy.

@en

Ten years of anti-vascular endothelial growth factor therapy.

@nl

prefLabel

Ten years of anti-vascular endothelial growth factor therapy.

@en

Ten years of anti-vascular endothelial growth factor therapy.

@nl

P1433

Q46407140-DC8EA529-657E-4304-AE08-EE853634BAB9

P1476

Q46407140-0D231FCE-DCEC-44E6-97F6-278FC542AD7E

P2093

Q46407140-5C21A0BC-66BD-4552-9370-F6AC8907B44D

Q46407140-768622D0-89A1-43D6-995B-87490AB00145

P2860

Q46407140-01FEA7C8-A4D5-4EA7-9969-4F333272A86B

Q46407140-0298F192-1A4A-4897-B026-EFD8994E3196

Q46407140-031908AC-E68D-4DF9-A486-362369D0C33E

Q46407140-0345111C-53BC-4635-BCF2-3E1930C98C93

Q46407140-03C79CA5-50AA-48BD-957B-ECB9D8F98CCD

Q46407140-05C283EF-4841-46DD-8037-95E9CA381A97

Q46407140-065CAEAC-D1B7-471F-865F-8B65509633FD

Q46407140-0671C38C-7B16-4651-829B-A9B8BFCA9C8D

Q46407140-06992419-EAEB-4487-A5EE-824F7515CB8B

Q46407140-08173A1E-9435-42C3-91AE-0541E8DF0D20

P2888

Q46407140-19B2BC78-4D31-4647-AEF1-0E8FBCB28015

P304

Q46407140-6963E508-1D62-4AC8-BE22-6F6C18CD4253

P31

Q46407140-7D7EDF78-A58A-4D80-9C74-6B35AC5817F0

P356

Q46407140-51CECD2C-7E27-4293-A54F-A794EAD5BC22

P433

Q46407140-53A3869C-D0AC-4C88-8C70-7C8BA5A27238

P478

Q46407140-5385D5C0-585C-43A5-B611-4006C750D0A7

P577

Q46407140-86247F1A-3C1E-4EEB-8F5F-A4165247F63D

P698

Q46407140-CD08D46A-9092-4675-965D-1797DF81F064

P921

Q46407140-800F25C4-A86A-4116-9010-395AF6FB2B34

P356

P1433

Nature Reviews Drug Discovery

P1476

Ten years of anti-vascular endothelial growth factor therapy.

@en

P2093

Anthony P Adamis

http://www.w3.org/2001/XMLSchema#string

Napoleone Ferrara

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex

Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

Vascular endothelial growth factor B, a novel growth factor for endothelial cells

Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor

The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia

P2888

P304

385-403

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRD.2015.17

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26775688

http://www.w3.org/2001/XMLSchema#string

P921